Spanjaart, Anne Mea
Ljungman, Per http://orcid.org/0000-0002-8281-3245
de La Camara, Rafael http://orcid.org/0000-0002-8189-5779
Tridello, Gloria
Ortiz-Maldonado, Valentín
Urbano-Ispizua, Alvaro
Barba, Pere http://orcid.org/0000-0003-1038-5197
Kwon, Mi http://orcid.org/0000-0002-3855-7774
Caballero, Dolores
Sesques, Pierre
Bachy, Emmanuel
Di Blasi, Roberta
Thieblemont, Catherine
Calkoen, Friso http://orcid.org/0000-0001-9059-0929
Mutsaers, Pim http://orcid.org/0000-0002-3924-8578
Maertens, Johan http://orcid.org/0000-0003-4257-5980
Giannoni, Livia
Nicholson, Emma
Collin, Matthew http://orcid.org/0000-0001-6585-9586
Vaz, Carlos Pinho
Metafuni, Elisabetta
Martinez-Lopez, Joaquin
Dignan, Fiona L.
Ribera, Josep-Maria
Nagler, Arnon
Folber, Frantisek
Sanderson, Robin
Bloor, Adrian http://orcid.org/0000-0003-4550-220X
Ciceri, Fabio
Knelange, Nina
Ayuk, Francis
Kroger, Nicolaus
Kersten, Marie José
Mielke, Stephan http://orcid.org/0000-0003-0167-6021
Article History
Received: 14 September 2021
Revised: 19 October 2021
Accepted: 21 October 2021
First Online: 8 November 2021
Competing interests
: There is no financial support for this work that could have influenced the outcomes described in the paper. However, particular authors report a potential competing interests, which is described below. VOM has received compensation for travel support from Kite/Gilead, Novartis, BMS/Celgene, Takeda and Janssen and consultant or advisory fees from Kite/Gilead, Novartis, BMS/Celgene and compensation for presentations from Kite/Gilead. PB has received honoraria from Amgen, BMS, Gilead, Incyte, Miltenyi Biotec, Novartis and Pfizer and funding from the Carlos III Health Institute FIS16/01433 and 20/00197, Asociación Española contra el Cáncer (Ideas Semilla 2019) and a PERIS 2018-2020 grant from the Generalitat de Catalunya (BDNS357800). MK has received consultancy fees and honoraria from Novartis, BMS/Cellgene, Kite/Gilead, and Pfizer. PS has received honoraria from Kite/Gilead, Novartis, and Chugai. RDB has received honoraria/hospitality from Gilead, Novartis, and Janssen. CT has received consultancy fees, advisory fees and honoraria from Novartis, BMS/Celgene, Roche, Janssen, Takeda, Kite/Gilead, Incyte and research funding from Roche and travel expenses from Novartis, BMS/Celgene, Roche, Janssen, Kite/Gilead. PM has received research funding from Astra Zeneca and consultancy fees from BMS/Celgene. EN has received research funding from Kite/Gilead, advisory board fees for Novartis and BMS/Celgene, travel support from Novartis and Kite/Gilead, speaker fees from Kite/Gilead. JML has received consultancy fees from Janssen, BMS, Novartis, Incyte, Roche, GSK and Pfizer and research funding from Roche, Novartis, Incyte, Astellas, and BMS. JMR received consultancy and speaker fees from Pfizer, Amgen, Shire, Ariad, Takeda and Novartis and research funding from Phizer, Amgen, Ariad, and Takeda. RS has received speakers fees and honoraria from Kite/Gilead and Novartis. AB has received honoraria from Kite/Gilead and Novartis. FA has received research funding from Mallinckrodt/ThekarosHonoraria from Novartis, BMS/Celgene, Janssen, Takeda, Mallinckrodt/Thekaros, Kite/Gilead, and Miltenyi Biomedicine. NK has received a research grant and honoraria from Novartis, Kite/Gilead, and BMS. SM has received funding from Celgene/BMS: Speakers bureau (via my institution); Novartis: Speakers bureau (via my institution); Gilead/Kite: Other: Travel support, Expert panel (via my institution); DNA Prime SA and funding from Speakers bureau (via my institution); Miltenyi: Other: Data safety monitoring board (via my institution) Immunicum: Other: Data safety monitoring board (via my institution). MJK has received research funding from Kite/Gilead and compensation for advisory boards and presentations and/or travel support from Kite/Gilead, Novartis, BMS/Celgene, and Miltenyi Biotec (to institution).